Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

R. Houston Thompson, James P. Allison, Eugene D. Kwon

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)442-447
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Issue number5
StatePublished - Sep 2006


  • CTLA-4
  • Costimulation
  • Immunotherapy
  • Prostatic neoplasms
  • T-lymphocyte

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this